Market Overview

UPDATE: Sterne Agee Reiterates Neutral Rating, Raises PT on athenahealth

Share:
Related ATHN
7 Biotech And Healthcare Picks For 2017 From Cantor Fitzgerald
Why 2017 Could Be An Inflection Year For Athenahealth

In a report published Monday, Sterne Agee Group reiterated its Neutral rating on athenahealth (NASDAQ: ATHN), and raised its price target from $72.00 to $80.00.

Sterne Agee noted, “The proposed acquisition of Epocrates (EPOC, NR, $11.68) announced last week has reignited investor interest in the stock, which had dropped nearly 30% following third quarter results. At 21x the consensus CY14 EBITDA estimate of $139 million, ATHN trades at a significant premium to the group (11x CY14). Our revised $80 price target is based on 20x our CY14 EBITDA estimate. This estimate does not incorporate any contribution from Epocrates. We await clarification on the terms of the financing from athenahealth. Our $80 target implies a P/E multiple of 50x on our CY14 EPS estimate of $1.59.”

athenahealth closed on Friday at $83.35.

Latest Ratings for ATHN

DateFirmActionFromTo
Jan 2017Cantor FitzgeraldInitiates Coverage OnOverweight
Jan 2017KeyBancUpgradesSector WeightOverweight
Dec 2016DoughertyInitiates Coverage OnBuy

View More Analyst Ratings for ATHN
View the Latest Analyst Ratings

Posted-In: Sterne Agee GroupAnalyst Color Price Target Analyst Ratings

 

Related Articles (ATHN)

View Comments and Join the Discussion!